Orforglipron

Orforglipron (research designation LY3502970) is an investigational once-daily small-molecule (non-peptide) oral glucagon-like peptide-1 (GLP-1) receptor agonist. It can be taken any time of the day without restrictions on food and water intake. It was discovered by Chugai Pharmaceutical and licensed by Eli Lilly in 2018. The compound has completed its full Phase 3 clinical development program (ATTAIN and ACHIEVE trials) and was submitted to the FDA in late 2025 for the obesity indication. It was granted a Commissioner's National Priority Voucher by the FDA. If approved, orforglipron would be the first oral non-peptide GLP-1 receptor agonist available for chronic weight management or type 2 diabetes.

The molecule is structurally distinct from peptide GLP-1 agonists. Native GLP-1, semaglutide, liraglutide, and most other GLP-1 agonists are peptides that require subcutaneous injection because peptide structures are degraded by gastric peptidases. Orforglipron is a small-molecule (non-peptide) compound that binds the GLP-1 receptor at a distinct allosteric site, producing the same downstream signaling without the peptide structure that limits oral bioavailability.

The clinical positioning is straightforward. Oral semaglutide (Rybelsus) is currently the only approved oral GLP-1 agonist, but it requires fasting administration (must be taken on an empty stomach with limited water, then no food for 30 minutes) due to its peptide structure and the need for SNAC absorption enhancement. Orforglipron's small-molecule structure removes these constraints, allowing flexible daily dosing.

The ATTAIN Phase 3 Program (Obesity)

The ATTAIN program is the Phase 3 development for orforglipron in obesity.

ATTAIN-1 (published in NEJM, September 2025). Phase 3 trial in 3,127 adults with obesity or overweight with a weight-related medical problem and without diabetes. 72 weeks of treatment. All three doses (6 mg, 12 mg, 36 mg) met the primary endpoint of superior body weight reduction compared with placebo. The highest dose (36 mg) produced average weight loss of approximately 27.3 lbs (12.4 percent). Discontinuation due to adverse events was 5.3 percent at 6 mg, 7.9 percent at 12 mg, and 10.3 percent at 36 mg versus 2.7 percent with placebo. No hepatic safety signal.

ATTAIN-2 (August 2025). Phase 3 trial in adults with obesity or overweight and type 2 diabetes. 72 weeks. Orforglipron 36 mg produced average weight loss of 10.5 percent (22.9 lbs) versus 2.2 percent (5.1 lbs) with placebo. A1C reduced by 1.8 percent at the highest dose. All three doses met the primary and key secondary endpoints. The lower weight-loss magnitude versus ATTAIN-1 reflects the established pattern that diabetic patients lose less weight than non-diabetic patients across all GLP-1 trials.

ATTAIN-MAINTAIN (December 2025). Phase 3 trial evaluating orforglipron for weight maintenance over 52 weeks after initial treatment with Wegovy (semaglutide) or Zepbound (tirzepatide) in patients from SURMOUNT-5. Orforglipron showed superior percent maintenance of body weight reduction compared with placebo. Participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved weight loss on average. This trial established the role of orforglipron as a maintenance therapy after injectable incretin weight loss.

The ATTAIN program enrolled more than 4,500 patients across global registration trials. Lilly submitted the NDA to the FDA for the obesity indication in late 2025 with FDA action expected in 2026.

The ACHIEVE Phase 3 Program (Type 2 Diabetes)

The ACHIEVE program is the Phase 3 development for orforglipron in type 2 diabetes.

ACHIEVE-1. Phase 3 trial in adults with type 2 diabetes inadequately controlled with diet and exercise. Orforglipron met the primary endpoint with A1C reductions of 1.2 percent (3 mg), 1.5 percent (12 mg), and 1.5 percent (36 mg) versus 0.4 percent with placebo. Weight reduction was 4.5 percent (3 mg), 5.8 percent (12 mg), and 7.6 percent (36 mg) versus 1.7 percent placebo. The first oral small-molecule GLP-1 to complete Phase 3.

ACHIEVE-3 (published in The Lancet, February 2026). Head-to-head Phase 3 trial comparing orforglipron with oral semaglutide (Rybelsus) in 1,698 adults with type 2 diabetes inadequately controlled on metformin. 52 weeks. Orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints, delivering significantly greater improvements in A1C and weight. This is the first head-to-head Phase 3 trial of orforglipron versus another GLP-1 agonist and supports the comparative efficacy claim.

The cumulative ACHIEVE program established orforglipron efficacy in type 2 diabetes with comparable or superior glycemic control to other GLP-1 agonists while maintaining the oral administration advantage.

Orforglipron binds the GLP-1 receptor as a small-molecule agonist. The downstream signaling is the same as for peptide GLP-1 agonists.

GLP-1 receptor activation. Standard incretin effects: appetite suppression through hypothalamic and brainstem GLP-1 receptors, slowed gastric emptying, glucose-dependent insulin secretion from pancreatic beta cells, reduced glucagon release from alpha cells.

Small-molecule binding site. Orforglipron binds the GLP-1 receptor at a site distinct from where native GLP-1 and peptide agonists bind. The receptor activation profile is similar but the binding chemistry allows oral absorption without peptide degradation concerns.

No food or water restrictions. Unlike Rybelsus, which uses sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) as an absorption enhancer and requires fasting administration, orforglipron's pharmacokinetics are not substantially affected by food or water intake. The compound can be taken at any time of day with normal meals.

Once-daily dosing. The pharmacokinetic profile supports once-daily oral administration. The dosing range tested in Phase 3 was 6 mg, 12 mg, and 36 mg daily.

The clinical pharmacology of orforglipron represents a significant departure from established GLP-1 agonists in formulation and administration without departing from the established receptor pharmacology and clinical effects.

Regulatory status

United States. Lilly submitted the NDA for orforglipron to the FDA in late 2025 for the obesity indication. FDA action is expected in 2026. The compound received a Commissioner's National Priority Voucher. Lilly has indicated confidence in ability to launch without supply constraints.

Global regulatory submissions. Lilly has indicated global submissions are underway in 2025-2026 timeframes following the completion of the Phase 3 program.

EU. EMA submission anticipated to follow the FDA approval. Standard pattern for new obesity drugs.

WADA status. Orforglipron is not currently named on the WADA Prohibited List as a specific substance. As a GLP-1 receptor agonist, it would fall under section S4 (Hormone and Metabolic Modulators) by analogy. Competitive athletes should expect TUE requirements similar to other GLP-1 agonists.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The Phase 3 safety profile of orforglipron has been described as consistent with injectable GLP-1 therapies. The most consistent findings are:

Gastrointestinal effects dominate. Nausea, diarrhea, vomiting, and constipation are most common during dose escalation. The pattern is similar to semaglutide and tirzepatide.

No hepatic safety signal. ATTAIN-1 specifically reported no hepatic concerns despite oral administration, which had been a theoretical concern for oral GLP-1 agonists.

Discontinuation rates ranged from 5.3 percent at the lowest dose to 10.3 percent at the highest dose in ATTAIN-1, versus 2.7 percent on placebo. This is comparable to injectable GLP-1 agents.

Mild heart rate increase consistent with GLP-1 class effects.

Standard contraindications apply, including personal or family history of medullary thyroid carcinoma or MEN2 syndrome (the boxed warning class effect for the GLP-1 family).

The safety profile is one of the central commercial advantages of orforglipron. The oral administration without food or water restrictions improves convenience, and the comparable safety profile to injectable agents removes the trade-off that oral semaglutide (Rybelsus) imposed through the fasting administration requirement.

The orforglipron clinical positioning is distinct.

Orforglipron vs Rybelsus (oral semaglutide). Both are oral GLP-1 agonists. Rybelsus requires fasting administration and has lower bioavailability than injectable semaglutide. Orforglipron has no food or water restrictions, more convenient daily administration. ACHIEVE-3 showed orforglipron outperforms oral semaglutide on primary and secondary endpoints in head-to-head trial.

Orforglipron vs injectable semaglutide (Ozempic/Wegovy). Injectable semaglutide produces approximately 15 percent weight loss in STEP-1 (Wegovy 2.4 mg). ATTAIN-1 showed orforglipron 36 mg producing approximately 12.4 percent weight loss. The injectable still has a slight efficacy edge but orforglipron has the oral convenience advantage.

Orforglipron vs tirzepatide (Zepbound). Tirzepatide produces approximately 22 percent weight loss in SURMOUNT-1. Orforglipron is the oral option with smaller maximum weight-loss effect but easier administration.

Orforglipron as maintenance therapy. ATTAIN-MAINTAIN established orforglipron as effective for maintaining weight loss after initial treatment with injectable Wegovy or Zepbound. This positions orforglipron as both initial therapy and as a step-down option after achieving target weight with injectable agents.

For practical positioning, orforglipron offers the oral administration advantage with efficacy approaching but not matching the strongest injectable GLP-1 agents. The trade-off between convenience and maximum efficacy will define the commercial positioning.